<DOC>
	<DOC>NCT02920515</DOC>
	<brief_summary>This is a prospective, multicentric, comparative, non-randomized interventional study in which subjects diagnosed with central precocious puberty (CPP) and early puberty (EP) were treated for 6 months to compare the effect with GnRHa and traditional Chinese medicines.</brief_summary>
	<brief_title>Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty</brief_title>
	<detailed_description>740 girls with CPP and EP participated in this study, all participates were divided into GnRHa group, traditional chinese medicines group and blank group. After at least six months therapy with GnRHa or traditional Chinese medicines, the investigators compare clinical parameters, sex hormone, bone age and ovarian ultrasound in three groups.</detailed_description>
	<mesh_term>Puberty, Precocious</mesh_term>
	<criteria>1. Premature appearance of secondary sexual characteristics: girls present with development of secondary sexual characteristics before 8, with breast induration as the earliest manifestation. 2. Accelerated linear growth: the annual growth rate is higher than normal. 3. Advanced bone age: the bone age is 1 or years more than the actual age 4. Enlargement of sexual glands: Bmode ultrasonography of pelvic cavity indicates the volumes of the uterus and ovaries have increased, and multiple ovarian follicles with a diameter&gt;4mm can be found in ovaries; 5. HPGA functions have been primed; serum gonadotropin and sexual hormone levels reach pubertal values. 6. Subjects should be willing and able to follow the study protocol during the study period. 7. Subjects should submit their parents' or guardians' written informed consent before initiation of the study procedure with nonnormal medical care. They should understand that subjects or their parents/guardians may withdraw the consent at any time without impairing future medical care. If the child is old enough to read and write, she should submit a separate consent form. 1. Patients with central nervous system diseases and thyroid diseases; 2. Patients with CHAinduced precocious puberty; 3. Patients with poor compliance.</criteria>
	<gender>Female</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>epidemiology</keyword>
	<keyword>treatment</keyword>
	<keyword>molecular pathological mechanism</keyword>
	<keyword>environmental disrupting chemicals</keyword>
</DOC>